Switch theme
Sign up to access all valuation multiples
Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. Its products are Children Qingfei oral liquid, Rana oil granules, Ejiao, and others.
1997
2.9K+
LTM Revenue $2.7B
LTM EBITDA $443M
$6.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Beijing Tongrentang Co has a last 12-month revenue (LTM) of $2.7B and a last 12-month EBITDA of $443M.
In the most recent fiscal year, Beijing Tongrentang Co achieved revenue of $2.6B and an EBITDA of $543M.
Beijing Tongrentang Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Beijing Tongrentang Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $443M | XXX | $543M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $411M | XXX | $387M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $224M | XXX | $212M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Beijing Tongrentang Co's stock price is CNY 38 (or $5).
Beijing Tongrentang Co has current market cap of CNY 52.1B (or $7.2B), and EV of CNY 44.9B (or $6.2B).
See Beijing Tongrentang Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.2B | $7.2B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Beijing Tongrentang Co has market cap of $7.2B and EV of $6.2B.
Beijing Tongrentang Co's trades at 2.4x EV/Revenue multiple, and 11.5x EV/EBITDA.
Equity research analysts estimate Beijing Tongrentang Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Beijing Tongrentang Co has a P/E ratio of 32.3x.
See valuation multiples for Beijing Tongrentang Co and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.2B | XXX | $7.2B | XXX | XXX | XXX |
| EV (current) | $6.2B | XXX | $6.2B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 14.1x | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.3x | XXX | 34.1x | XXX | XXX | XXX |
| EV/FCF | 26.3x | XXX | 186.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeijing Tongrentang Co's last 12 month revenue growth is 9%
Beijing Tongrentang Co's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.3M for the same period.
Beijing Tongrentang Co's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Beijing Tongrentang Co's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Beijing Tongrentang Co and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | -9% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beijing Tongrentang Co acquired XXX companies to date.
Last acquisition by Beijing Tongrentang Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Beijing Tongrentang Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Beijing Tongrentang Co founded? | Beijing Tongrentang Co was founded in 1997. |
| Where is Beijing Tongrentang Co headquartered? | Beijing Tongrentang Co is headquartered in China. |
| How many employees does Beijing Tongrentang Co have? | As of today, Beijing Tongrentang Co has 2.9K+ employees. |
| Is Beijing Tongrentang Co publicy listed? | Yes, Beijing Tongrentang Co is a public company listed on SHG. |
| What is the stock symbol of Beijing Tongrentang Co? | Beijing Tongrentang Co trades under 600085 ticker. |
| When did Beijing Tongrentang Co go public? | Beijing Tongrentang Co went public in 1997. |
| Who are competitors of Beijing Tongrentang Co? | Similar companies to Beijing Tongrentang Co include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Beijing Tongrentang Co? | Beijing Tongrentang Co's current market cap is $7.2B |
| What is the current revenue of Beijing Tongrentang Co? | Beijing Tongrentang Co's last 12 months revenue is $2.7B. |
| What is the current revenue growth of Beijing Tongrentang Co? | Beijing Tongrentang Co revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Beijing Tongrentang Co? | Current revenue multiple of Beijing Tongrentang Co is 2.3x. |
| Is Beijing Tongrentang Co profitable? | Yes, Beijing Tongrentang Co is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Beijing Tongrentang Co? | Beijing Tongrentang Co's last 12 months EBITDA is $443M. |
| What is Beijing Tongrentang Co's EBITDA margin? | Beijing Tongrentang Co's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Beijing Tongrentang Co? | Current EBITDA multiple of Beijing Tongrentang Co is 14.1x. |
| What is the current FCF of Beijing Tongrentang Co? | Beijing Tongrentang Co's last 12 months FCF is $237M. |
| What is Beijing Tongrentang Co's FCF margin? | Beijing Tongrentang Co's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Beijing Tongrentang Co? | Current FCF multiple of Beijing Tongrentang Co is 26.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
